Synthetic approach to designed chemical structures
AssigneeRegents of the University of Minnesota
InventorsBeulah H. Gray, Judith R. Haseman, Kevin Mayo, Arjan W. Griffioen
Life of this patent
Estimating the term…
Abstract
This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.
Claims21
A water soluble peptide comprising βpep-19 (SEQ ID NO:19).
A method for treating a bacteria infection comprising administering to a mammal an amount of a pharmaceutical composition effective to inhibit the bacterial infection, wherein the pharmaceutical composition comprises:
- (a) a peptide comprising βpep-19 (SEQ ID NO:19);
- and
- (b) a pharmaceutically acceptable carrier.
A method for inhibiting TNF-α levels in a mammal comprising administering a therapeutically effective amount of a pharmaceutical composition comprising:
- (a) a peptide comprising βpep-19 (SEQ ID NO:19);
- and
- (b) a pharmaceutically acceptable carrier.
A method for inhibiting endothelial cell proliferation comprising administering to a mammal an effective amount of a composition comprising:
- a peptide comprising βpep-19 (SEQ ID NO:19).
A method for promoting inter-cellular adhesion molecule expression comprising administering to a mammal an effective amount of a composition comprising:
- a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting angiogenesis in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting angiogenesis in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising a peptide comprising βpep-19 (SEQ ID NO:19);
- and a pharmaceutically acceptable carrier.
A method for inhibiting tumorigenesis in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising a peptide comprising βpep-19 (SEQ ID NO:19) and a pharmaceutically acceptable carrier.
A method for inhibiting bacterial infection in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting TNF-α levels in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting endothelial cell proliferation in a cell culture, the method comprising contracting cells with an effective amount of a composition comprising:
- a peptide demonstrating endothelial cell proliferation inhibition comprising βpep-19 (SEQ ID NO:19).
A method for promoting inter-cellular adhesion molecule expression in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising:
- a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting inter-cellular adhesion molecule expression down regulation in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising:
- a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting inter-cellular adhesion molecule expression down regulation in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising:
- a peptide comprising βpep-19 (SEQ ID NO:19).
A method for inhibiting leukocyte/endothelial cell adhesion in a cell culture, the method comprising contacting cells with an effective amount of a composition comprising βpep-19 (SEQ ID NO:19).
A method of increasing leukocyte cell infiltration in a mammal, the method comprising administering to the mammal an effective amount of a composition comprising βpep-19 (SEQ ID NO:19);
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.